Can a One-Two punch wake up and destroy hidden HIV?

NCT ID NCT07577986

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a combination therapy to target hidden HIV reservoirs. Twenty HIV-positive adults on stable antiretroviral therapy will receive chidamide (to reactivate dormant virus) followed by infusions of engineered NK cells designed to kill the reactivated cells. The main goal is to check safety, but researchers will also look for signs that the viral reservoir is shrinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chidamide combined with NKG2D CAR-NK cells
What this could lead to: If it works, this could point toward a functional cure for HIV, allowing patients to control the virus without lifelong medication.
What could go wrong: This is a very early, small trial (20 people) focused on safety. The 'shock and kill' approach has not yet been proven in humans, and there are risks like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (HUMAN IMMUNODEFICIENCY VIRUS)

Contacts and locations

Locations

the first affiliated hospital of Zhejiang university school of medicine, Hangzhou, Zhejiang 310000

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.